Drug intelligence / Profile preview

dexisometheptene mucate

Development stage: Phase 2
Lead developer: Tonix Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Dexisometheptene mucate is the (R)-enantiomer of isometheptene, a sympathomimetic small molecule investigated for the treatment of tension-type headache. It acts as a potent agonist at the imidazoline-1-receptor and has vasoconstrictive properties. Dexisometheptene mucate was studied in clinical trial NCT02423408 under the code name TNX-201 for single tension-type headache but its development was discontinued in 2016[2][3][4][7]. The drug’s mechanism involves indirect sympathomimetic activity, likely contributing to its antimigraine effects.

Other names: (R)-isometheptenedexisomethepteneisometheptene, (r)-dexisometheptene mucate [USAN]

Targets

I1R (Nischarin)

Beyond the preview

Go deeper on dexisometheptene mucate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexisometheptene mucate.

Explore the full profile